ABSTRACT

Background

Currently, studies have shown that anti-CGRP monoclonal antibodies are effective drugs for the prophylaxis and treatment of episodic migraine. Therefore, for the first time, we classified and concluded 10 treatment regimens according to the different doses, drugs, routes of administration, and courses of treatment, so as to provide a reference for further clinical studies.

Methods

We studied relevant randomized controlled trials (RCTs) published before August 2020 on PubMed, Embase, Ovid MEDLINE, Web of Science, and the Cochrane Central Register of Controlled Trials.

Results

Eleven RCTs involving 6397 patients were included in our analysis. Network meta-analysis results suggested that in the comparison of the average migraine days per month, Erenumab (140 mg), Galcanezumab (120 mg, 240 mg), Fremanezumab (225 mg, 675 mg) were superior to placebo, Erenumab(7 mg), and the difference was statistically significant; Fremanezumab (225 mg, 675 mg) was superior to Erenumab (21 mg, 70 mg), and the difference was statistically significant; in the comparison of average medication days of acute migraine-specific drug per month, Erenumab (70 mg, 140 mg), Galcanezumab (120 mg, 240 mg), Fremanezumab (225 mg, 675 mg) was superior to placebo, and Erenumab (140 mg) and Galcanezumab (120 mg, 240 mg) were superior to Erenumab (70 mg), and the difference was statistically significant; there was no statistically significant difference in the average migraine days in the last month or in the medication days of acute migraine-specific drug.

Conclusion

Fremanezumab (225 mg) and Galcanezumab (120 mg) may be the best clinical protocol after a comprehensive assessment.

中文翻译：

---

不同抗CGRP单克隆抗体方案预防和治疗发作性偏头痛疗效和安全性的网络Meta分析

摘要

背景

目前研究表明，抗CGRP单克隆抗体是预防和治疗发作性偏头痛的有效药物。因此，我们首次根据不同剂量、药物、给药途径和疗程，对10个治疗方案进行分类总结，为进一步的临床研究提供参考。

方法

我们研究了 2020 年 8 月之前在 PubMed、Embase、Ovid MEDLINE、Web of Science 和 Cochrane Central Register of Controlled Trials 上发表的相关随机对照试验 (RCT)。

结果

我们的分析纳入了 11 项涉及 6397 名患者的随机对照试验。网络荟萃分析结果表明，在每月平均偏头痛天数的比较中，Erenumab（140 mg）、Galcanezumab（120 mg、240 mg）、Fremanezumab（225 mg、675 mg）优于安慰剂、Erenumab（7 mg） )，差异有统计学意义；Fremanezumab（225 mg、675 mg）优于Erenumab（21 mg、70 mg），差异有统计学意义；在急性偏头痛特异性药物每月平均用药天数的比较中，Erenumab（70 mg、140 mg）、Galcanezumab（120 mg、240 mg）、Fremanezumab（225 mg、675 mg）优于安慰剂，而Erenumab（ 140 mg）和Galcanezumab（120 mg、240 mg）优于Erenumab（70 mg），差异有统计学意义；

结论

Fremanezumab (225 mg) 和 Galcanezumab (120 mg) 可能是综合评估后的最佳临床方案。